Talat Imran - 03 Jun 2026 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: RANI
Reported as of: 03 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 18:14:52 UTC
Prior SEC filing: 23 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Svai Sanford, Attorney-in-Fact

Key filing fact

Talat Imran filed Form 4 for Rani Therapeutics Holdings, Inc. (RANI) on 05 Jun 2026.

Key facts

This page summarizes Talat Imran's Form 4 filing for Rani Therapeutics Holdings, Inc. (RANI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2026, 18:14.

Change

Previous filing in this sequence was filed on 23 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001869579 Primary reporting owner

Imran Talat

Relationship: Chief Executive Officer, Director
Address: C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE, SAN JOSE
Signature: /s/ Svai Sanford, Attorney-in-Fact
Signature date: 05 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RANI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +3,800,000
Change %
Price: $0.000000^*
Shares after: 3,800,000
Date: 03 Jun 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 3,800,000
Exercise price: $0.8750
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from April 1, 2026, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through each such vesting date.